药明康德
(603259)
| 流通市值：2458.44亿 | | | 总市值：2965.86亿 |
| 流通股本：24.73亿 | | | 总股本：29.84亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 32,856,716,508.86 | 20,799,281,882.46 | 9,654,595,304.28 | 39,241,431,359.88 |
| 营业收入 | 32,856,716,508.86 | 20,799,281,882.46 | 9,654,595,304.28 | 39,241,431,359.88 |
| 二、营业总成本 | 21,256,267,707.67 | 14,014,556,298.92 | 6,712,128,987.72 | 27,342,268,206.88 |
| 营业成本 | 17,538,098,637.79 | 11,554,124,208.9 | 5,574,529,171.26 | 22,964,515,460.62 |
| 税金及附加 | 273,965,204.62 | 170,017,517.84 | 84,736,857.59 | 301,181,005.49 |
| 销售费用 | 569,374,574.48 | 394,367,252.66 | 194,051,886.09 | 745,388,381.87 |
| 管理费用 | 1,858,526,669.26 | 1,175,416,378.21 | 562,794,264.61 | 2,879,341,988.34 |
| 研发费用 | 825,650,523.1 | 514,427,140.15 | 224,408,414.09 | 1,238,524,969.42 |
| 财务费用 | 190,652,098.42 | 206,203,801.16 | 71,608,394.08 | -786,683,598.86 |
| 其中:利息费用 | 226,711,873.66 | 146,262,529.53 | 65,761,071.64 | 216,033,816.34 |
| 其中:利息收入 | 678,141,337.63 | 444,165,181 | 204,414,638.64 | 626,757,006.25 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -34,435,917.65 | -182,183,014.07 | -45,938,551.48 | 186,957,574.92 |
| 加:投资收益 | 4,098,539,874.75 | 3,669,213,003.27 | 1,537,653,139.2 | 604,162,381.66 |
| 资产处置收益 | -69,873,339.23 | -12,844,822.74 | -13,400,009.25 | -36,063,443.51 |
| 资产减值损失(新) | -410,113,443.18 | -321,420,123.36 | -156,213,198.67 | -1,236,257,969.76 |
| 信用减值损失(新) | -346,855,872.7 | -189,218,242.77 | -78,773,317.83 | -337,578,609.74 |
| 其他收益 | 228,351,689.81 | 182,845,973.63 | 106,954,396.76 | 499,791,631.57 |
| 四、营业利润 | 15,066,061,792.99 | 9,931,118,357.5 | 4,292,748,775.29 | 11,580,174,718.14 |
| 加:营业外收入 | 12,551,180.53 | 7,692,961.06 | 152,777.95 | 22,254,764.5 |
| 减:营业外支出 | 41,544,623.08 | 31,394,760.59 | 13,008,002.36 | 62,617,843.56 |
| 五、利润总额 | 15,037,068,350.44 | 9,907,416,557.97 | 4,279,893,550.88 | 11,539,811,639.08 |
| 减:所得税费用 | 2,830,874,889.18 | 1,247,068,437.43 | 564,424,709.84 | 1,972,072,099.9 |
| 六、净利润 | 12,206,193,461.26 | 8,660,348,120.54 | 3,715,468,841.04 | 9,567,739,539.18 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 12,339,724,609.74 | 8,791,888,321.78 | 3,733,866,312.31 | 11,396,829,426.64 |
| 终止经营净利润 | -133,531,148.48 | -131,540,201.24 | -18,397,471.27 | -1,829,089,887.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 12,075,512,956.92 | 8,560,882,627.56 | 3,671,960,950.47 | 9,450,308,427.78 |
| 少数股东损益 | 130,680,504.34 | 99,465,492.98 | 43,507,890.57 | 117,431,111.4 |
| 扣除非经常损益后的净利润 | 9,522,413,145.23 | 5,582,126,598.19 | 2,329,266,627 | 9,988,102,785.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 4.25 | 3.01 | 1.29 | 3.28 |
| (二)稀释每股收益 | 4.21 | 2.99 | 1.28 | 3.26 |
| 八、其他综合收益 | -95,953,157.33 | -37,885,690.49 | 118,473,436.43 | 185,718,884.52 |
| 归属于母公司股东的其他综合收益 | -84,806,802.74 | -32,103,995.36 | 120,103,150.04 | 188,583,091.93 |
| 九、综合收益总额 | 12,110,240,303.93 | 8,622,462,430.05 | 3,833,942,277.47 | 9,753,458,423.7 |
| 归属于母公司股东的综合收益总额 | 11,990,706,154.18 | 8,528,778,632.2 | 3,792,064,100.51 | 9,638,891,519.71 |
| 归属于少数股东的综合收益总额 | 119,534,149.75 | 93,683,797.85 | 41,878,176.96 | 114,566,903.99 |
| 公告日期 | 2025-10-27 | 2025-07-29 | 2025-04-29 | 2025-03-18 |
| 审计意见(境内) | | | | 标准无保留意见 |